ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
2016 · Annals of Oncology · 3,333 citations
https://doi.org/10.1093/annonc/mdw235
E
Eduardo Díaz‐Rubio
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
572
Papers
22.9K
Citations
65
h-index
231
i10-index
Eduardo Díaz‐Rubio is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology & Genetic factors in colorectal cancer. The author has an h-index of 65, co-authored 487 publications.
ORCID: 0000-0003-2792-5348Papers by this author
worksXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
2011 · British Journal of Cancer · 224 citations
https://doi.org/10.1038/bjc.2011.201
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
2006 · British Journal of Cancer · 124 citations
https://doi.org/10.1038/sj.bjc.6603059
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
2017 · Annals of Oncology · 96 citations
https://doi.org/10.1093/annonc/mdx501
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
2018 · British Journal of Cancer · 80 citations
https://doi.org/10.1038/s41416-018-0293-5
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging
2017 · BMC Cancer · 75 citations
https://doi.org/10.1186/s12885-017-3185-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat